drugset / Trial / NCT00234858

Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)

NCT00234858 ↗

Phase 4 Completed 280 enrolled Abbott
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

Timeline

Start
2004-03
Primary completion
2006-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrochlorothiazide Unknown 25 mg —
Comparator Losartan Other / unclassified 100 mg —
Comparator Verapamil Other / unclassified 240 mg —
Comparator trandolapril Small molecule 4 mg —